Rheumatoid arthritis update: Tocilizumab superior to adalimumab as monotherapy
KEY POINT
Monotherapy with the disease modifying antirheumatic drug (DMARD) tocilizumab (Actemra—Genentech) was superior to monotherapy with adalimumab (Humira—AbbVie) for improving the signs and symptoms of rheumatoid arthritis (RA) in patients intolerant to the non-biological DMARD methotrexate.
SOURCES
Gabay C et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomized, double blind, controlled phase 4 trial. Lancet. 2013;381:1541–50.
De Vita S. Tociluzumab versus adalimumab for rheumatoid arthritis [commentary]. Lancet. 2013;381:1515–7.
